Literature DB >> 11739693

Disturbance of tumor necrosis factor alpha-mediated beta interferon signaling in cervical carcinoma cells.

Anastasia Bachmann1, Brigitte Hanke, Rainer Zawatzky, Ubaldo Soto, Jan van Riggelen, Harald zur Hausen, Frank Rösl.   

Abstract

In the present study we show that malignant human papillomavirus (HPV)-positive cells lost their ability to synthesize endogenous beta interferon (IFN-beta) upon tumor necrosis factor alpha (TNF-alpha) treatment. IFN-beta transcription, however, was reinducible in nonmalignant HPV-positive cells, which was confirmed in functional protection assays against encephalomyocarditis virus or vesicular stomatitis virus infections. Addition of neutralizing antibodies against IFN-beta blocked the antiviral effect, excluding the possibility that other IFN types were involved. Conversely, both malignant and immortalized cells could be protected against viral cytolysis when either IFN-beta, IFN-alpha, or IFN-gamma was added exogenously. This indicates that only the cross talk between TNF-alpha and the IFN-beta pathways, and not IFN-alpha/beta and IFN-gamma signaling in general, is perturbed in cervical carcinoma cells. Notably, full virus protection was restricted exclusively to nonmalignant cells, indicating that the antiviral effect correlates with the growth-inhibitory and virus-suppressive properties of TNF-alpha. The IFN-regulatory factors IRF-1 and p48 (ISGF3gamma) emerged as key regulatory molecules in the differential IFN-beta response, since their transcription was either absent or only inefficiently enhanced in tumorigenic cells upon treatment with TNF-alpha. Inducibility of both genes, however, became reestablished in cervical carcinoma cells, which were complemented to nontumorigenicity after somatic cell hybridization. Complementation was paralleled by the entire reconstitution of cytokine-mediated IFN-beta expression and the ability of TNF-alpha to exert an antiviral state. In contrast, under conditions where tumor suppression was not accomplished upon somatic cell hybridization, neither expression of IRF-1, p48, and IFN-beta nor antiviral activity could be restored.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11739693      PMCID: PMC135709          DOI: 10.1128/jvi.76.1.280-291.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

Review 1.  Structure and function of the interferon-beta enhanceosome.

Authors:  T Maniatis; J V Falvo; T H Kim; T K Kim; C H Lin; B S Parekh; M G Wathelet
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1998

Review 2.  Macrophage-derived growth factors.

Authors:  D A Rappolee; Z Werb
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

Review 3.  Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines.

Authors:  M D Miller; M S Krangel
Journal:  Crit Rev Immunol       Date:  1992       Impact factor: 2.214

Review 4.  Treatment of cervical intraepithelial neoplasia and invasive squamous cell carcinoma by interferon.

Authors:  J Bornstein; Y Ben-David; J Atad; B Pascal; M Revel; H Abramovici
Journal:  Obstet Gynecol Surv       Date:  1993-04       Impact factor: 2.347

5.  Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex.

Authors:  U Soto; B C Das; M Lengert; P Finzer; H zur Hausen; F Rösl
Journal:  Oncogene       Date:  1999-05-27       Impact factor: 9.867

6.  Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas.

Authors:  K Kleine-Lowinski; R Gillitzer; R Kühne-Heid; F Rösl
Journal:  Int J Cancer       Date:  1999-07-02       Impact factor: 7.396

7.  Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells.

Authors:  T M Chen; G Pecoraro; V Defendi
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

8.  Langerhans' cell counts and cervical intraepithelial neoplasia in women with human immunodeficiency virus infection.

Authors:  A Spinillo; P Tenti; R Zappatore; F De Seta; E Silini; S Guaschino
Journal:  Gynecol Oncol       Date:  1993-02       Impact factor: 5.482

9.  Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons.

Authors:  M A Khan; W H Tolleson; J D Gangemi; L Pirisi
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids.

Authors:  F Rösl; M Lengert; J Albrecht; K Kleine; R Zawatzky; B Schraven; H zur Hausen
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  10 in total

1.  Cervical cancer and CYP2E1 polymorphisms: implications for molecular epidemiology.

Authors:  Paula M Ferreira; Raquel Catarino; Deolinda Pereira; Ana Matos; Daniela Pinto; Ana Coelho; Carlos Lopes; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2005-12-22       Impact factor: 2.953

Review 2.  The interferon signaling network and transcription factor C/EBP-beta.

Authors:  Hui Li; Padmaja Gade; Weihua Xiao; Dhan V Kalvakolanu
Journal:  Cell Mol Immunol       Date:  2007-12       Impact factor: 11.530

3.  Interference with energy metabolism by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induces HPV suppression in cervical carcinoma cells and apoptosis in the absence of LKB1.

Authors:  Julia Nafz; Johanna De-Castro Arce; Verena Fleig; Andrea Patzelt; Sybille Mazurek; Frank Rösl
Journal:  Biochem J       Date:  2007-05-01       Impact factor: 3.857

4.  Regulation of MCP-1 chemokine transcription by p53.

Authors:  Katrin Hacke; Bladimiro Rincon-Orozco; Gilles Buchwalter; Simone Y Siehler; Bohdan Wasylyk; Lisa Wiesmüller; Frank Rösl
Journal:  Mol Cancer       Date:  2010-04-20       Impact factor: 27.401

5.  Expression and functional analysis of Toll-like receptor 4 in human cervical carcinoma.

Authors:  Yongjun Wang; Yanjie Weng; Ying Shi; Xi Xia; Shixuan Wang; Hua Duan
Journal:  J Membr Biol       Date:  2014-05-31       Impact factor: 1.843

6.  The functional role of Notch signaling in HPV-mediated transformation is dose-dependent and linked to AP-1 alterations.

Authors:  Florianne E Henken; Johanna De-Castro Arce; Frank Rösl; Leontien Bosch; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  Cell Oncol (Dordr)       Date:  2012-01-24       Impact factor: 6.730

7.  RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation.

Authors:  Susanne V Schmidt; Stefanie Seibert; Barbara Walch-Rückheim; Benjamin Vicinus; Eva-Maria Kamionka; Jennifer Pahne-Zeppenfeld; Erich-Franz Solomayer; Yoo-Jin Kim; Rainer M Bohle; Sigrun Smola
Journal:  Oncotarget       Date:  2015-04-20

8.  Palmitic acid is a toll-like receptor 4 ligand that induces human dendritic cell secretion of IL-1β.

Authors:  Dequina A Nicholas; Kangling Zhang; Christopher Hung; Shane Glasgow; Aruni Wilson Aruni; Juli Unternaehrer; Kimberly J Payne; William H R Langridge; Marino De Leon
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

9.  Association of tumor necrosis factor-alpha promoter variants with risk of HPV-associated oral squamous cell carcinoma.

Authors:  Lei Jin; Erich M Sturgis; Yang Zhang; Zhigang Huang; Xicheng Song; Chao Li; Qingyi Wei; Guojun Li
Journal:  Mol Cancer       Date:  2013-07-19       Impact factor: 27.401

10.  Characterization of global transcription profile of normal and HPV-immortalized keratinocytes and their response to TNF treatment.

Authors:  Lara Termini; Enrique Boccardo; Gustavo H Esteves; Roberto Hirata; Waleska K Martins; Anna Estela L Colo; E Jordão Neves; Luisa Lina Villa; Luiz Fl Reis
Journal:  BMC Med Genomics       Date:  2008-06-27       Impact factor: 3.063

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.